[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"West China Second University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":372},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,41,57,85,109,135,154,176,199,220,241,265,286,306,327,348],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100644416","emotional-distress-and-pathologic-response-in-locally-advanced-gastricgej-adenocarcinoma-100644416",false,"NCT07662070","Emotional Distress and Pathologic Response in Locally Advanced Gastric\u002FGEJ Adenocarcinoma","A Prospective Observational Study of the Association Between Pretreatment Emotional Distress and Pathologic Response to Perioperative Immunotherapy in Locally Advanced Gastric\u002FGastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n1. Willing to participate in this study.\n2. Age \\>18 years; both sexes are eligible.\n3. Histologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.\n4. Resectable locally advanced disease as assessed by imaging and\u002For multidisciplinary team evaluation, generally corresponding to AJCC 8th edition stage II-III disease, including cT3-4a with any N category or any T with node-positive disease, without distant metastasis.\n5. Planned to receive neoadjuvant therapy followed by curative-intent surgery.\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n7. No prior systemic antitumor treatment for the current tumor at baseline.\n8. Able to understand and complete questionnaire assessments.\n9. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Presence of distant metastasis, peritoneal metastasis, or loss of curative treatment opportunity as determined by clinical evaluation.\n2. Prior neoadjuvant chemotherapy, immunotherapy, radiotherapy, or other systemic antitumor treatment for the current tumor.\n3. Severe cognitive impairment, acute psychiatric disorder, or any condition that precludes completion of questionnaire assessments.\n4. Current treatment with antidepressants, anxiolytics, or other psychotropic medications with any of the following within 4 weeks before baseline assessment: initiation, discontinuation, change in medication type, dose adjustment of 50% or more, or addition of a second or more psychotropic medication.\n5. Any other condition judged by the investigator to make the participant unsuitable for enrollment.","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","3 Years","OBSERVATIONAL","This is a single-center, prospective observational cohort study designed to evaluate the association between pretreatment emotional distress and pathologic response to perioperative immunotherapy in patients with locally advanced gastric or gastroesophageal junction adenocarcinoma. A total of 120 patients planned for neoadjuvant immunotherapy followed by curative surgery will be enrolled. Emotional distress will be assessed using the PHQ-9 and GAD-7 before treatment initiation and at prespecified time points during treatment. Participants will be classified into an emotional distress group or a non-emotional distress group according to predefined criteria. The primary endpoint is major pathological response (MPR). Secondary endpoints include pathological complete response (pCR), R0 resection rate, event-free survival (EFS), recurrence-free survival (RFS), and overall survival (OS). Exploratory analyses will assess dynamic changes in emotional distress and their associations with peripheral stress markers, peripheral immune markers, and tumor immune microenvironment features.",[25,26,27,28],"Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Emotional Distress","Pathologic Response","NOT_YET_RECRUITING","2026-06-17",{"date":32,"type":33},"2026-06-23","ACTUAL",{"date":35,"type":20},"2026-06-26",{"date":37,"type":20},"2028-12-31",{"name":39,"class":40},"West China Second University Hospital","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":53,"startDateStruct":54,"completionDateStruct":55,"leadSponsor":56,"locationsCount":4},"100644388","objective-sleep-characteristics-and-neoadjuvant-immunotherapy-response-in-gastricgej-cancer-100644388","NCT07662005","Objective Sleep Characteristics and Neoadjuvant Immunotherapy Response in Gastric\u002FGEJ Cancer","Objective Sleep Characteristics and Response to Neoadjuvant Immunotherapy in Locally Advanced Gastric\u002FGastroesophageal Junction Adenocarcinoma: A Prospective Observational Study","Inclusion Criteria:\n\n1. Age greater than 18 years, regardless of sex.\n2. Histologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.\n3. Locally advanced, resectable disease as assessed by imaging or a multidisciplinary team, based on the 8th edition of the AJCC staging system, typically cT3-4a, any N, or any T with N-positive disease, corresponding to stage II-III disease, without distant metastasis.\n4. Scheduled to receive neoadjuvant therapy followed by radical surgery.\n5. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1.\n6. No prior systemic anticancer therapy for the current tumor at study baseline.\n7. Willing to participate in the study and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Presence of distant metastasis, peritoneal metastasis, or disease considered no longer suitable for curative-intent treatment.\n2. Prior neoadjuvant chemotherapy, immunotherapy, radiotherapy, or other systemic anticancer therapy for the current tumor.\n3. Severe cognitive impairment, acute psychiatric disorder, or any other condition that prevents the participant from completing study procedures.\n4. Current treatment with antidepressants, anxiolytics, sedative-hypnotics, or other psychotropic medications, with any of the following occurring within 4 weeks before enrollment:\n\n   1. Increase or decrease in the dose of the relevant medication by 25% or more from the previous maintenance dose;\n   2. Initiation, discontinuation, or replacement of antidepressants, anxiolytics, sedative-hypnotics, or other psychotropic medications;\n   3. Adjustment of treatment due to worsening anxiety, depression, insomnia, or other psychiatric or psychological symptoms;\n   4. Any medication change or psychological condition judged by the investigator to potentially affect sleep monitoring results or study compliance.\n5. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for this study.",{"count":19,"type":20},"This prospective observational study will enroll 120 patients with locally advanced gastric or gastroesophageal junction adenocarcinoma who are scheduled to receive neoadjuvant immunotherapy followed by radical surgery. Non-invasive objective sleep monitoring will be performed during the neoadjuvant treatment period to assess sleep characteristics, including sleep duration, sleep efficiency, device-estimated deep sleep proportion, nocturnal awakenings, sleep regularity, heart rate, and heart rate variability. The primary objective is to evaluate the association between objective sleep characteristics and major pathological response (MPR) after neoadjuvant immunotherapy. This study will not alter standard treatment decisions, surgical procedures, or perioperative management.",[25,26,51,52],"Sleep","Pathological Response",{"date":32,"type":33},{"date":35,"type":20},{"date":37,"type":20},{"name":39,"class":40},{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":65,"minAge":66,"maxAge":17,"enrollmentInfo":67,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":69,"conditions":70,"keywords":75,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":83,"locationsCount":84},"100632302","a-multicenter-cohort-study-of-duchenne-and-becker-muscular-dystrophy-in-western-chinese-children-100632302","NCT07511920","A Multicenter Cohort Study of Duchenne and Becker Muscular Dystrophy in Western Chinese Children","A Real-World, Multicenter Cohort Study on the Natural History of Duchenne and Becker Muscular Dystrophy in Children From Western China","WEST-DBMD","Inclusion Criteria:\n\n* Male participants with genetically confirmed diagnosis of Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD)\n* Age range: 1 to 18 years old (adjust to your actual age limit)\n* Ability to complete study assessments and follow-up visits\n* Participants or legal guardians provide written informed consent\n\nExclusion Criteria:\n\n* Participants with other neuromuscular disorders that may confound natural history data\n* Participation in another interventional clinical trial that could affect disease progression\n* Severe comorbidities that prevent completion of study assessments\n* Inability to provide informed consent or comply with study procedures","MALE","1 Year",{"count":68,"type":20},500,"This is a prospective, multicenter, longitudinal observational cohort study aimed at understanding the progression of Duchenne Muscular Dystrophy (DMD). The primary objective is to identify and integrate key biomarkers from multiple sources-including motor function assessments, body composition (muscle and fat distribution), clinical laboratory tests, and cardiopulmonary imaging-to delineate comprehensive disease trajectories. By analyzing how these factors change over time in a large cohort, the study seeks to develop a robust model that can identify patterns of disease progression. The ultimate goal is to generate evidence that may aid in forecasting individual patient outcomes and inform the future development of personalized rehabilitation and therapeutic strategies.",[71,72,73,74],"Muscular Dystrophy, Becker","Muscular Dystrophy","Muscular Dystrophy (DMD)","Muscular Dystrophy, Duchenne",[76],"Duchenne Muscular Dystrophy; Becker Muscular Dystrophy; Natural History; Multicenter Cohort Study; China; Predictive Model","2026-03-30",{"date":79,"type":33},"2026-04-06",{"date":81,"type":20},"2026-04-20",{"date":37,"type":20},{"name":39,"class":40},1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":91,"minAge":17,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100632006","comparison-of-high-definition-electronic-magnifying-endoscopy-with-image-enhanced-technology-versus-colposcopy-in-the-detection-of-cervical-and-vaginal-lesions-100632006","NCT07508072","Comparison of High-Definition Electronic Magnifying Endoscopy With Image-Enhanced Technology Versus Colposcopy in the Detection of Cervical and Vaginal Lesions","Inclusion Criteria:\n\n* ① Aged 18-65 years, with indications for colposcopy (HPV16\u002F18 positive; HPV non-16\u002F18 positive with LCT ≥ ASCUS; HPV negative with LCT ≥ LSIL; persistent HPV infection ≥ 1 year).\n\n  * Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* ① Women who are pregnant or breastfeeding.\n\n  * Acute reproductive tract infection, severe coagulation disorders. ③ History of radiotherapy for malignant tumors, study participants with severe mental illness.\n\n    * Underage women.","FEMALE","65 Years",{"count":94,"type":20},270,"INTERVENTIONAL",[97],"NA","1. Primary Objective:\n\n   To compare the diagnostic accuracy of high-definition electronic magnifying endoscopy combined with image-enhanced technology versus colposcopy for cervical and vaginal lesions.\n2. Secondary Objectives:\n\nTo evaluate and compare the sensitivity, specificity, positive predictive value, and negative predictive value of the two examination methods, and to assess the differences between the two techniques in image characteristics, such as lesion border clarity and visualization of microvascular structures.",[100],"Cervical Disease","2026-03-27",{"date":103,"type":33},"2026-04-02",{"date":105,"type":20},"2026-03-28",{"date":107,"type":20},"2030-03-28",{"name":39,"class":40},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":116,"maxAge":17,"enrollmentInfo":117,"targetDuration":4,"studyType":95,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},"100626086","modified-lch-iii-regimen-with-or-without-luvometinib-for-multisystem-pediatric-langerhans-cell-histiocytosis-100626086","NCT07431060","Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis","Modified LCH-III Regimen Versus Modified LCH-III Regimen Combined With Luvometinib in the Treatment of Multisystem Pediatric Langerhans Cell Histiocytosis: A Multicenter, Open-Label, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Children aged 0-18 years, of either sex.\n2. Pathologically confirmed diagnosis of Langerhans cell histiocytosis (LCH) with positive staining for CD1a and\u002For CD207 (Langerin), and no prior treatment specifically directed against LCH.\n3. Multisystem involvement of LCH, as determined by clinical and imaging evaluation.\n4. Provision of written informed consent (by parent\u002Flegal guardian and, where appropriate, assent from the child), with willingness to comply with the study treatment regimen and follow-up assessments.\n\nExclusion Criteria:\n\n1. Presence of any other significant underlying medical condition, including but not limited to primary immunodeficiency disorders, congestive heart failure, renal insufficiency, chronic viral hepatitis, HIV infection, or status post solid organ transplantation.\n2. History of a second (secondary) malignancy.\n3. QTcF interval \\> 0.47 seconds on electrocardiogram performed prior to enrollment.\n4. Ophthalmologic screening prior to enrollment revealing retinal vein occlusion, retinal pigment epithelial detachment, or other clinically significant ocular abnormalities that, in the opinion of the investigator, contraindicate participation.\n5. LCH harboring Class 3 MEK pathway mutations, specifically the following alterations: L98\\_I103del, L98\\_K104del, P105\\_A106del, P105\\_I107delinsL, L101\\_I103delinsF, E102\\_I103delinsF, E102\\_I103del, E102\\_I103delinsV, E102\\_I103delinsVN, E102\\_K104delinsQ, or I103\\_A106del.\n6. Refusal or inability to provide written informed consent (or assent, as applicable).","0 Years",{"count":19,"type":20},[97],"Langerhans cell histiocytosis (LCH) is the most common histiocytic disorder in children, caused by excessive proliferation and accumulation of Langerhans cells (a type of immune cell) in various body tissues. The annual incidence is about 2.6-8.9 cases per million children.Clinical presentation varies widely.\n\nMild (low-risk) cases may resolve spontaneously or cause minimal issues with excellent outcomes. Severe multisystem LCH involves multiple organs, particularly high-risk sites such as liver, spleen, or bone marrow, leading to poorer prognosis and potential life-threatening complications without appropriate treatment.Standard first-line therapy for many children is prednisone (a corticosteroid) plus vinblastine (chemotherapy). Trials like LCH-III show near-100% survival in low-risk disease, but long-term survival drops to \\~80% in high-risk cases. Reactivation occurs in \\~37% of low-risk patients post-treatment, and \\~50% of children eventually develop resistance, resulting in progression or relapse. Treatment failure heightens risks of long-term sequelae, including growth retardation, endocrine dysfunction, and neurological damage, severely impacting quality of life.\n\nMore than half of LCH cases harbor the BRAF V600E mutation, activating the MAPK pathway abnormally. This has driven development of targeted MAPK inhibitors (e.g., vemurafenib, dabrafenib, trametinib), which demonstrate strong efficacy and acceptable safety (mainly manageable skin rash) in relapsed\u002Frefractory pediatric cases, with no reported secondary malignancies to date. These agents provide rapid symptom relief and durable control, though monotherapy often fails to eradicate abnormal cells in multisystem disease, leading to relapse after discontinuation.\n\nNo MAPK inhibitors were previously approved specifically for LCH. In 2025, luvometinib (developed by Fosun Pharma, China; a selective MEK1\u002F2 inhibitor) received approval in China for adult LCH and histiocytic neoplasms. Adult studies showed \\~83% objective response rate and \\~74% progression-free at ≥12 months, with mostly mild side effects (skin issues, hypertriglyceridemia) and no discontinuations due to serious toxicity.\n\nLaboratory evidence indicates MAPK overactivation confers apoptosis resistance to LCH cells; combining MAPK inhibitors with chemotherapy may enhance cell killing and leverage chemotherapy-induced immune microenvironment changes for better clearance.\n\nSmall studies and real-world data in refractory LCH support this: combination regimens yielded low relapse rates (especially with prolonged therapy), 100% responses in some pediatric cohorts with sustained remission and no added severe toxicity, and notably lower relapse (20% vs 75% with inhibitor alone) in our center's early experience with LCH-III backbone plus MAPK inhibitor.\n\nThis multicenter randomized trial will enroll children with multisystem LCH, assigning them to modified standard LCH-III chemotherapy alone or the same regimen combined with luvometinib, to evaluate whether adding this targeted agent improves outcomes.",[121],"Langerhans Cell Histiocytosis (LCH)",[123,124],"Langerhans Cell Histiocytosis","Luvometinib","RECRUITING","2026-02-20",{"date":128,"type":33},"2026-02-24",{"date":130,"type":20},"2026-02-13",{"date":132,"type":20},"2030-12-31",{"name":39,"class":40},11,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":116,"maxAge":17,"enrollmentInfo":142,"targetDuration":4,"studyType":95,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":153,"locationsCount":134},"100621481","luvometinib-in-pediatric-ss-lch-with-special-site-singlemultifocal-bone-lesions-100621481","NCT07371182","Luvometinib in Pediatric SS-LCH With Special-site Single\u002FMultifocal Bone Lesions","A Multi-center, Open-label, Single-arm Study of Luvometinib Monotherapy in Pediatric Langerhans Cell Histiocytosis With Single-system Special-site Single and Multifocal Bone Involvement","Inclusion Criteria:\n\n1. Children aged 0-18 years, both sexes.\n2. Pathologically confirmed diagnosis of LCH (CD1a+ and\u002For CD207+), with no prior treatment specific to LCH.\n3. Patients assessed as having single-system multifocal bone involvement, single-site bone involvement at central nervous system risk sites (central nervous system risk sites include craniofacial region \\[excluding parietal, occipital, and frontal bones\\], orbital, ear, and oral regions), or single-site vertebral bone involvement with intraspinal space-occupying lesion compressing the spinal cord.\n4. Signed informed consent, willing to receive treatment according to this protocol and undergo follow-up.\n\nExclusion Criteria:\n\n1. Patients with other underlying diseases, such as primary immunodeficiency, heart failure, renal insufficiency, hepatitis virus infection, HIV infection, post-organ transplantation, etc.\n2. Secondary malignancy.\n3. QTcF \\> 0.47 seconds on electrocardiogram prior to enrollment.\n4. Ophthalmologic screening prior to enrollment reveals retinal vein occlusion, retinal pigment epithelial detachment, or other ocular diseases.\n5. Patients with LCH carrying category 3 MEK mutations, specifically the following mutation sites: L98\\_I103del, L98\\_K104del, P105\\_A106del, P105\\_I107delinsL, L101\\_I103delinsF, E102\\_I103delinsF, E102\\_I103del, E102\\_I103delinsV, E102\\_I103delinsVN, E102\\_K104delinsQ, I103\\_A106del.\n6. Refusal to sign the informed consent form.",{"count":143,"type":20},62,[97],"Langerhans cell histiocytosis (LCH) is the most common type of histiocytic disorder in children, affecting about 2.6 to 8.9 out of every million kids each year. It can look very different from one child to another-some cases get better on their own-but when it affects special bones (like the base of the skull, temporal bone, eye socket, or spine) or when there are multiple bone lesions in one system, children often face a higher risk of long-term complications and the disease coming back.Current guidelines in China and around the world recommend treating these children with whole-body therapy, usually a chemotherapy combination of vinblastine and prednisone. However, even with longer treatment courses, about 27.6% of children with multiple bone lesions still have the disease return, and less than 70% stay free of events after 5 years. Some even develop lasting nerve system problems.\n\nIn recent years, researchers discovered that nearly all children with LCH have overactive MAPK signaling pathways in their cells. This discovery opened the door to using MAPK inhibitors as a new treatment. Studies have shown that these drugs work well and are safe for children with relapsed or hard-to-treat LCH. Even better, in some kids with single-system bone disease, the disease did not come back after stopping the drug-suggesting it might even cure certain cases.\n\nLuvometinib (also called FCN-159), a new MAPK inhibitor developed by Fosun Pharma in Shanghai, was approved in 2025 for treating adult LCH. A Phase II clinical study showed very encouraging results: 82.8% of patients saw their disease improve or disappear, and 74.4% stayed free of progression after 12 months. The drug was well tolerated, with side effects that were mild and manageable-no serious problems forced anyone to stop treatment.Compared to traditional chemotherapy, luvometinib has fewer and milder side effects, does not weaken the immune system, and lets children continue normal daily life and school. It is a simple oral pill taken once a day, so there's no need for intravenous lines or hospital stays, making treatment much easier and improving quality of life for both the child and the family.",[121],"2026-01-18",{"date":149,"type":33},"2026-01-27",{"date":151,"type":20},"2026-06-19",{"date":132,"type":20},{"name":39,"class":40},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":91,"minAge":17,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":84},"100608415","exploring-gut-microbiome-differences-in-female-cancer-patients-with-varied-ovarian-function-and-fertility-outcomes-following-immune-checkpoint-inhibitor-therapy-100608415","NCT07201259","Exploring Gut Microbiome Differences in Female Cancer Patients With Varied Ovarian Function and Fertility Outcomes Following Immune Checkpoint Inhibitor Therapy","Inclusion Criteria:\n\nCollect serum hormone levels post-ICIs treatment to observe the impact of ICIs therapy on female patients.\n\n* Informed consent must be obtained and documented at the research center prior to initiating any trial procedures.\n* Female patients aged 18-38 years.\n* Patients with histologically confirmed solid tumors or soft tissue sarcomas diagnosed via open surgery, laparoscopic surgery, or core needle biopsy.\n* Patients scheduled to receive ICIs therapy or combination therapy including ICIs;\n* Normal ovarian function and fertility prior to treatment, defined as regular menstrual cycles, normal serum FSH, LH, E2, P, and AMH levels, and normal gynecological ultrasound findings;\n* No use of sex hormone medications within 6 months prior to enrollment, including but not limited to estrogens, anti-estrogens hormones, hormonal contraceptives, etc.;\n* No use of antibiotics or probiotics within 3 months prior to enrollment;\n* Availability of blood and stool specimens before and after treatment, with the subject's consent to provide these specimens to the central laboratory for study purposes, including but not limited to: i. Potential gut microbiota-related research. ii. Potential metabolite-related research;\n* Expected survival \\>12 weeks;\n* ECOG performance status 0-2;\n* Adequate organ function, including:\n* Bone marrow function: Neutrophil count ≥1500\u002FµL; Platelet count ≥100,000\u002F µL; Hemoglobin ≥10g\u002FdL\n* Liver function: Total bilirubin ≤1.5 times upper limit of normal (ULN) or direct bilirubin ≤1.0 times ULN; AST and ALT ≤2.5 times ULN, must be ≤5 times ULN if liver metastases present\n* Renal function: Serum creatinine ≤1.5 times ULN, or creatinine clearance\n\n  * 60 mL\u002Fmin (calculated using Cockcroft-Gault formula) ;\n* Understand the trial protocol and have the ability to comply with the trial plan throughout its duration, including cooperating with any required treatments, examinations, tests, follow-ups, and questionnaires;\n* Patient is willing to cooperate with ICIs treatment and subsequent follow-up.\n\nExclusion Criteria:\n\n* Individuals involved in the planning or implementation of the study;\n* Concurrent use of other tumor treatment modalities during the study, including but not limited to: chemotherapy, radiotherapy, immunotherapy, microbial therapy, traditional Chinese medicine, and other investigational therapies;\n* History of bilateral ovarian-related surgery;\n* Patients with prior radiotherapy or chemotherapy causing irreversible damage to ovarian function;\n* Individuals with known allergy to ICIs or their components;\n* Patients with known non-response to immunomodulatory therapy;\n* Patients with unexplained menstrual irregularities or long-term hormone medication use;\n* Patients with chronic gastrointestinal disease or known dysbiosis (e.g., Crohn's disease, ulcerative colitis);\n* Patients who frequently consume fermented foods;\n* Patients who underwent major surgery within 3 weeks prior to study initiation or have not yet recovered from surgery;\n* Subjects with other malignancies within the past 3 years;\n* Patients with severe, uncontrolled medical conditions or those deemed by the investigator to be generally unsuitable for study participation, including but not limited to: active viral infections such as HIV, hepatitis B, hepatitis C; severe cardiovascular disease, uncontrolled ventricular arrhythmias, myocardial infarction within the past 3 months; uncontrolled grand mal seizures, unstable spinal cord compression, superior vena cava syndrome, or other psychiatric conditions affecting informed consent; uncontrolled hypertension despite medication; immunodeficiency (excluding splenectomy) or other conditions the investigator deems likely to expose the subject to high toxicity risk;\n* Any history or current clinical evidence suggesting potential for confounding study results, compromising patient compliance throughout the study, or acting against the patient's best interests;\n* Receipt of platelet or red blood cell transfusion within 3 days prior to initiation of study drug treatment;\n* Pregnant or lactating patients, or patients planning pregnancy during the study period.\n* Clinically unresolved prior treatment toxicity (≥ Grade 2, excluding alopecia, neuropathy, lymphopenia, or skin hypopigmentation);","38 Years",{"count":162,"type":20},40,"The goal of this observational study is to evaluate the impact of Immune Checkpoint Inhibitor (ICI) treatment on ovarian function and fertility, and to explore the role of gut microbiota in female cancer patients of reproductive age (18-38 years) receiving ICI therapy. The main questions it aims to answer are:\n\nDoes ICI treatment alter serum hormone levels (FSH, LH, E2, P, AMH) associated with ovarian function and fertility?\n\nAre there differences in gut microbiota composition and metabolites between patients with different ovarian function and fertility outcomes after ICI treatment?\n\nWhat are the potential mechanisms by which gut microbiota influences ovarian function and fertility in patients receiving ICIs?\n\nResearchers will compare patients with preserved ovarian function versus those with impaired ovarian function after ICI treatment to identify differences in gut microbiota and metabolic profiles.\n\nParticipants will:\n\nProvide blood samples (10 ml per collection) at enrollment and after each of the 6 treatment cycles for hormone level testing and potential future analyses.\n\nProvide stool samples at the same time points for gut microbiota metagenomic sequencing and metabolite analysis.\n\nUndergo regular clinical assessments and follow-ups as part of their standard ICI treatment.",[165],"Malignant Tumors",[167],"immune checkpoint inhibitors, female, ovarian function, fertility","2025-09-23",{"date":170,"type":33},"2025-10-01",{"date":172,"type":20},"2025-10-10",{"date":174,"type":20},"2026-10-10",{"name":39,"class":40},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":91,"minAge":17,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":95,"phases":186,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":196,"leadSponsor":198,"locationsCount":84},"100567082","comparing-the-efficacy-of-tu-less-and-vnotes-for-hysterectomy-of-enlarged-uterus-100567082","NCT06663553","Comparing the Efficacy of TU-LESS and vNOTES for Hysterectomy of Enlarged Uterus","Protocol for a Comparative Study of the Efficacy of Transumbilical Laparoendoscopic Single-site Surgery (TU-LESS) and Transvaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) in Hysterectomy Performed on Patients With Enlarged Uterus: A Prospective Single-blinded, Randomized Clinical Trial","Inclusion Criteria:\n\n* Eligible women aged 18-70 years.\n* Women with indications for enlarged uterine volumes who are planning to under go total hysterectomy. Uterine size should exceed that of a 3-month pregnancy (uterine weight ≥ 280 g).\n* Patients are willing to be randomly assigned to undergo any of both approaches.\n* Patients who are willing to sign the informed consent form.\n\nExclusion Criteria:\n\n* Individuals who are virgins or have vaginal stenosis.\n* Patients requiring concurrent surgical intervention for conditions such as ovarian cysts or lesions of the vulva, vagina, appendix, etc.\n* presence of uterus exceeding approximately 20 gestational weeks in size (about 900-1000g), which is beyond the limitations of a single-site laparoscopic approach due to concerns regarding technical feasibility and safety\n* Presence of malignancy or strong suspicion of malignancy that may alter the planned surgical approach.\n* History of two or more pelvic surgeries or suspected severe pelvic adhesions (rectovaginal examination suggesting rectovaginal endometriosis or limited uterine mobility).\n* History of peritoneal dialysis, pelvic radiation therapy and pelvic tuberculosis treated with laparoscopic surgery.\n* Patients with prolapse or pelvic inflammation.\n* Diabetes mellitus with poor blood glucose control.\n* Body mass index greater than 30 kg\u002Fm².","70 Years",{"count":185,"type":20},210,[97],"Enlarged uterus is frequently encountered in clinical practice, and its incidence due to conditions such as adenomyosis, uterine fibroids, and other gynecological disorders has steadily increased over the years statistically. For example, greater healthcare awareness has led to more frequent early diagnoses of these conditions, contributing to the observed rise in incidence. Additionally, increasing life expectancy results in more women reaching the perimenopausal and postmenopausal stages, during which conditions like uterine fibroids and adenomyosis become more prevalent. For these women, hysterectomy (removal of the entire uterus) is often the recommended option of treatment.\n\nWith advances in surgical techniques over recent decades, there has been a notable shift from traditional open abdominal surgeries to minimally invasive approaches. Laparoscopic surgery has been widely adopted, significantly reducing the size and number of incisions required, thereby promoting faster recovery, minimizing postoperative pain, and reducing the risk of complications.\n\nHowever, conventional multi-port laparoscopic hysterectomy still presents certain challenges, such as large uterus extraction following resection, and concerns about healing of incisions. In contrast, innovative techniques like Transumbilical Laparoendoscopic Single-Site Surgery(TU-LESS) and Transvaginal Natural Orifice Transluminal Endoscopic Surgery(vNOTES) both take advantage of natural anatomical openings to achieve minimal or no visible scarring. Studies demonstrate that these techniques provide superior outcomes in terms of reduced pain, faster recovery, and quicker return to daily activities compared to traditional multi-port laparoscopic approaches.\n\nYet a direct comparison of the efficacy of these two methods in real-world, particularly for enlarged uterus, remains inconclusive. Thus this study aims to evaluate and compare the outcomes of these two techniques in patients with enlarged uteri. Participants will be randomly assigned to receive one of the two surgical approaches, ensuring an unbiased comparison of the efficacy of the procedures in terms of healing status and recovery time.",[189,190,191],"Enlarged Uterus","Adenomyosis","Uterine Fibroids (UF)","2025-09-16",{"date":194,"type":33},"2025-09-18",{"date":170,"type":20},{"date":197,"type":20},"2028-10",{"name":39,"class":40},{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":91,"minAge":17,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":84},"100526303","cardiac-magnetic-resonance-monitoring-of-immune-checkpoint-inhibitor-related-cardiotoxicity-100526303","NCT06132984","Cardiac Magnetic Resonance Monitoring of Immune Checkpoint Inhibitor-related Cardiotoxicity","Cardiac Magnetic Resonance Monitoring of Immune Checkpoint Inhibitor-related Cardiotoxicity in Patients With Gynecologic Malignancies: A Cohort Study","Inclusion Criteria:\n\n* 1\\. Female patients aged 18 to 75 years, diagnosed with gynecological malignancies through histology or cytology.\n* 2\\. Patients who are preparing for monotherapy or combination therapy with ICIs.\n* 3\\. Voluntary signing of informed consent form.\n* 4\\. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* 5\\. Expected survival of at least 6 months.\n\nExclusion Criteria:\n\n* 1\\. Previously received ICIs treatment.\n* 2\\. With allergies or contraindications to ICIs.\n* 3\\. Confirmed to be brain metastasis.\n* 4\\. Patients who have major surgery within 4 weeks prior to or following the screening period.\n* 5\\. Patients who have received systemic corticosteroids (at a dose equivalent to \\>10 mg prednisone per day) or other immunosuppressive medications within 14 days prior to enrollment or during the study period; however, the following situations are allowed for inclusion:\n\n  1. the use of topical or inhaled corticosteroids is permitted;\n  2. short-term (≤7 days) use of corticosteroids for prevention or treatment of non-autoimmune diseases is allowed.\n* 6\\. Left ventricular ejection fraction (LVEF) ≤50%, or New York Heart Association functional classification (NYHA) ≥III.\n* 7\\. Coronary heart disease, cardiomyopathy, congenital heart disease, valvular heart disease and pericardial diseases with confirmed diagnosis.\n* 8\\. Lack of autonomous capacity, or a documented history of mental disease.\n* 9\\. MRI contraindications: Pacemakers, neurostimulators, artificial metal heart valves, arterial aneurysm clips, intraocular metallic foreign bodies, inner ear implants, metal prostheses, metal limbs, metal joints, and any other metallic implants or foreign objects; severe hyperthermia patients; claustrophobia; severe respiratory conditions that prevent breath-holding.","75 Years",{"count":208,"type":20},22,"This study is a prospective cohort clinical research that analyzes the changes in CMR parameters before and after immune checkpoint inhibitors (ICIs) therapy in patients with gynecologic malignancies. It also evaluates the value of CMR parameters in predicting long-term outcomes. The baseline assessment will be conducted prior to ICIs treatment, followed by multiple assessments during the medication process including within one week prior to cycle 3 , within the week prior to cycle 5 , 1 year after the first dose, and 2 years after the first dose. Assessment will also be conducted after discontinuation of ICIs medication. The assessment includes clinical assessment, CMR imaging, echocardiography, serum cardiac injury biomarkers, etc. Cancer therapy-related cardiac dysfunction (CTRCD), survival, and major adverse cardiac events (MACE) will be followed up.",[211],"Immune Checkpoint Inhibitors, Cardiotoxicity","2025-07-29",{"date":214,"type":33},"2025-08-01",{"date":216,"type":33},"2023-11-23",{"date":218,"type":20},"2027-12-31",{"name":39,"class":40},{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":16,"minAge":116,"maxAge":17,"enrollmentInfo":227,"targetDuration":4,"studyType":95,"phases":229,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":84},"100594698","phase-2-real-world-study-of-darafenib-or-trametinib-and-clofarabine-for-high-riskrecurrentrefractory-langerhans-cell-histiocytosis-in-children-100594698","NCT07022834","Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk\u002FRecurrent\u002FRefractory Langerhans Cell Histiocytosis in Children","A Real-world Investigation of the Combination of Darafenib or Trametinib and Clofarabine in the Treatment of High-risk, Recurrent, or Refractory Pediatric Patients With Langerhans Cell Histiocytosis.","Inclusion Criteria:\n\n1. Children aged 0-18 with LCH (CD1a+\u002FCD207+);\n2. Initial LCH diagnosis with hematopoietic, liver, or spleen involvement;\n3. LCH patients with disease progression or reactivation after chemotherapy (e.g., prednisone, vincristine, cytarabine, clarithromycin) or targeted therapy;\n4. Consent to treatment and follow-up;\n5. ECOG score ≥ 2, Lansky score ≥ 50, organ function suitable for chemotherapy.\n\nExclusion Criteria:\n\n1. Other underlying diseases (e.g., primary immunodeficiency, heart\u002Fkidney failure, hepatitis, HIV, organ transplant);\n2. Secondary tumor;\n3. Recent chemotherapy, radiotherapy, or MAPK inhibitor use with lingering adverse effects;\n4. Ongoing nephrotoxic drug use;\n5. Refusal to consent.\n\nExit Criteria:\n\n1. Allergies to dabrafenib or trametinib and clofarabine；\n2. Disease progression after 3 months on dabrafenib or trametinib；\n3. Severe toxic side effects from clofarabine (grade 4 non-infectious non-hematological toxicity, SIRS, capillary leak syndrome)； 4）The doctor recommends halting the current treatment plan for the patient's benefit.",{"count":228,"type":20},20,[230],"PHASE2","Langerhans cell histiocytosis (LCH) is the most common histiocytosis in children, with an incidence of 2.6-8.9 per million. It is an inflammatory myeloid tumor with varied symptoms. Mild cases often resolve spontaneously, while severe cases can affect multiple organs and be life-threatening. LCH affecting the liver, spleen, or hematopoietic system has a poor prognosis and is high-risk group. The LCH-III study showed that low-risk children respond well to prednisone and vinblastine, with nearly 100% survival, but high-risk children's survival is about 80%, with a 30% reactivation rate.Long-term studies reveal that about 50% of patients are resistant to prednisone and vinblastine, leading to progression and recurrence.\n\nExcept combination of prednisone and vinblastine, cladribine (introduced in 1998) and MAPK inhibitors (introduced in 2014), have lowered the mortality rate of LCH in children. Cladribine, a nucleoside analogue, is used for treating recurrent acute myeloid leukemia in children by disrupting DNA synthesis. In the LCH-98-S regimen, low-risk children with LCH responded well to moderate doses of cladribine, but 44% of high-risk children still faced disease progression. Later studies showed that high-dose cladribine with medium-dose cytarabine increased survival in refractory LCH from 30% to 85%, but also raised chemotherapy toxicity, with some cases experiencing severe hematological toxicity and half of the deaths resulting from chemotherapy complications. Clofarabine, a nucleoside analogue, inhibits ribonucleotide reductase and DNA polymerase, offering stronger anti-tumor effects and fewer side effects than cladribine and fludarabine in treating refractory leukemia. Case reports show that LCH patients unresponsive to cladribine improve with clofarabine treatment at moderate doses (25mg\u002Fm2\u002Fday). A retrospective study of 58 LCH patients using clofarabine (25mg\u002Fm2\u002Fday) showed an 87% progression-free survival rate after one year. While the main side effect was grade 3 or higher hematological toxicity, 98.3% of patients tolerated it and completed treatment. Further prospective studies are needed to determine the optimal dose, duration, long-term efficacy, and complications of clofarabine in children with LCH.\n\nResearch indicates that childhood LCH is often linked to mutations in MAPK pathway genes, with over half of cases involving BRAFV600E mutations. MAPK inhibitors, like vemurafenib, dabrafenib and trametinib, are effective for relapsed and refractory LCH, but they don't eliminate malignant clones, leading to disease reactivation after stopping treatment. Some BRAF-deficient mutation LCH patients resist vemurafenib and dabrafenib, but trametinib can manage the disease in these cases. Activation of the MAPK pathway increases BCL2L1 expression in LCH cells, and rapamycin fails to induce apoptosis in BRAFV600E+ LCH cells, enhancing resistance to cell death. MAPK inhibitors combined with chemotherapy are theoretically more effective at inducing apoptosis in LCH cells and resetting the immune environment to eliminate malignant clones. Two clinical studies confirm their safety and efficacy in treating refractory recurrent LCH. In a follow-up of 10 LCH cases treated with nucleotide analogues and MAPK inhibitors, only 2 patients relapsed after a short treatment duration. Additionally, 19 children with BRAFV600E mutation LCH were treated with cladribine, cytarabine, and vemurafenib, achieving a 100% response rate. Nearly 80% completed treatment without recurrence, and no increase in side effects was observed.\n\nSince 2020, our center treated nearly 40 LCH patients with MAPK inhibitors, including 14 combined with LCH-III chemotherapy. Follow-ups show no severe toxic side effects, aligning with literature. However, most high-risk patients, especially those who stopped oral MAPK inhibitors, had disease reactivation. Two high-risk patients with liver involvement achieved complete liver lesion regression with cladribine. This clinical study aims to assess the efficacy and safety of dabrafenib or trametinib and clofarabine for high-risk\u002Frecurrent\u002Frefractory LCH in children.",[121],"2025-06-07",{"date":235,"type":33},"2025-06-15",{"date":237,"type":33},"2025-06-01",{"date":239,"type":20},"2030-06-01",{"name":39,"class":40},{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":66,"maxAge":21,"enrollmentInfo":248,"targetDuration":4,"studyType":95,"phases":250,"briefSummary":251,"conditions":252,"keywords":254,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":264},"100583801","peginterferon--2b-injection-for-aerosol-therapy-in-pediatric-respiratory-syncytial-virus-pneumonia-100583801","NCT06881056","Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia","A Phase 2 Multicenter, Randomized, Open-label Study to Evaluate the Pharmacokinetic, Safety and Efficacy of Peginterferon Alfa-2b Injection in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea.","Inclusion Criteria:\n\n* (1)Age: 1 year ≤ age ≤ 3 years; (2) Gender: Both male and female participants are eligible; (3) According to the 9th edition of \"Zhu Fute's Practical Pediatrics,\" meet the following diagnostic criteria: a. RSV test positive; b. Clinical manifestations: Fever, cough, wheezing; c. Physical signs: Rapid breathing and moist rales in the lungs; (4) Time: The time from the onset of the child's illness to the signing of the informed consent form is within 72 hours (starting from the occurrence of any symptom such as fever, cough, or wheezing); (5) Informed consent: The legal guardian of the child understands and signs the informed consent form (if the legal guardians are the parents, both parents need to sign together).\n\nExclusion Criteria:\n\n* (1) Presence of any of the following clinical symptoms before enrollment: a. Poor general condition, with altered consciousness, refusal to eat, or signs of dehydration; b. Hypoxemia: Presence of cyanosis, rapid breathing (RR ≥ 50 breaths per minute), stridor, nasal flaring, tracheal tug, oxygen saturation \\\u003C 92%, and intermittent apnea; c. Extrapulmonary complications; d. Chest X-ray or CT: Multilobar lung infiltrates, pleural effusion, pneumothorax, atelectasis, lung necrosis, and lung abscess; e. Hyperpyrexia: Persistent high fever for more than 5 days; f. Presence of critical complications such as respiratory failure and circulatory failure; (2) Allergy history and treatment history: a. Receiving antiviral drug treatment with interferon, ribavirin, acyclovir, ganciclovir, or vidarabine monophosphate within 30 days before screening or currently; b. Receiving immunoglobulin treatment within 30 days before screening or currently; c. Known hypersensitivity to interferon or its components, or a clear history of other allergies that make participation in this study inappropriate; d. Use of other investigational drugs within 3 months before screening or within 5 half-lives (whichever is longer), or currently participating in a clinical trial for a medical device at the time of screening; (3) Disease history and current medical history: a. History of congenital heart disease, severe malnutrition, abnormal immune system function, or other serious diseases of major organ systems; b. Severe liver or renal dysfunction; c. History of viral infections such as HBV, HCV, HIV; d. Past or current history of malignant tumors; e. Past history of epilepsy, or history and family history of neurological\u002Fpsychiatric disorders; (4) Other conditions: Subjects deemed unsuitable for participation in this trial by the investigator.",{"count":249,"type":20},90,[97],"This is a multicenter, randomized, open-label, parallel-controlled, prospective clinical study. It aims to evaluate the efficacy and safety of aerosolized Peginterferon α-2b injection in the treatment of pediatric respiratory syncytial virus pneumonia. The overall study is divided into a screening period, a treatment period, and a follow-up period. Eligible children with respiratory syncytial virus pneumonia will be randomly assigned to the experimental group 1, experimental group 2, and the control group at a ratio of 1:1:1.",[253],"Respiratory Syncytial Virus (RSV)",[253,255],"Peginterferon α-2b injection","2025-03-11",{"date":258,"type":33},"2025-03-18",{"date":260,"type":33},"2024-07-17",{"date":262,"type":20},"2026-03-31",{"name":39,"class":40},2,{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":91,"minAge":17,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":95,"phases":273,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":84},"100556745","conversion-of-evidence-and-applied-research-on-intermittent-catheterization-after-radical-hysterectomy-100556745","NCT06529107","Conversion of Evidence and Applied Research on Intermittent Catheterization After Radical Hysterectomy","Inclusion Criteria:\n\n* Age ≧ 18 years old\n* Radical cervical cancer surgery and intermittent catheterization were performed at the Institute's hospital\n* Patients or their family members can operate a smartphone\n* No cognitive or psychiatric disorders, and can communicate effectively\n\nExclusion Criteria:\n\n* People with serious heart, brain, lung and other important organ diseases\n* People with water, electrolyte, acid-base balance disorders at the beginning of intermittent catheterization\n* People with previous serious renal diseases, bladder and urethra surgery\n* People with urinary tract infections\n* People who did not complete all interventions or data collection\n* People who voluntarily withdrew from the study or died during the study period;\n* Refuse to participate in this study",{"count":272,"type":20},70,[97],"In this study, the investigators summarize the existing best evidence of intermittent catheterization in patients after radical cervical cancer surgery from the perspective of clinical translation of evidence through systematic search, evaluation and evidence integration, construct a nursing protocol of intermittent catheterization for patients after radical cervical cancer surgery based on the best evidence combined with the clinical context, and explore the clinical application effect of the above nursing protocol. It will provide a reference basis for the development of the standardization and management of intermittent catheterization for postoperative patients with cervical cancer in China, as well as the development of guidelines for intermittent catheterization after radical cervical cancer surgery.",[276,277],"Intermittent Catheterization","Conversion of Evidence","2024-07-25",{"date":280,"type":33},"2024-07-31",{"date":282,"type":33},"2024-01-01",{"date":284,"type":20},"2024-12-31",{"name":39,"class":40},{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":91,"minAge":17,"maxAge":183,"enrollmentInfo":292,"targetDuration":4,"studyType":95,"phases":294,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":4},"100555275","phase-2-a-study-of-ql1706-an-anti-pd-1ctla-4-combined-antibody-combined-with-albumin-bound-paclitaxel-and-bevacizumab-in-the-treatment-of-platinum-resistant-recurrent-ovarian-cancer-100555275","NCT06509971","A Study of QL1706 (an Anti-PD-1\u002FCTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer","Inclusion Criteria:\n\n1. Voluntary signing of a written ICF.\n2. Age ≥18 years, ≤75 years, female.\n3. The Eastern Cooperative Oncology Group (ECOG) physical fitness score was 0 or 1.\n4. Expected survival ≥3 months.\n5. Histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.\n6. Patients with platinum-resistant recurrent ovarian cancer (including fallopian tube and peritoneal cancer) were defined as progression within 6 months after platinum-based chemotherapy.\n7. At least one measurable lesion according to RECIST v1.1, and this lesion is amenable to repeated accurate measurements according to RECIST v1.1. Lesions that have received radiation therapy can be considered as target lesions if they are clearly progressive and measurable on the basis of imaging.\n8. Determination of good organ function through the following requirements:\n\n   A) hematology (no blood component and cell growth factor support therapy was used for 7 days before study initiation) :\n\n   I. ANC ≥1.5 × 109 L (1.500 MM3) in absolute neutrophil; II. Platelet count ≥100 × 109\u002FL (100,000\u002FMM3) ; III. Hemoglobin ≥90 g\u002FL.\n\n   B) kidneys:\n\n   I. Creatinine clearance \\* (CrCl) calculated value ≥50 mL\u002Fmin\n\n   \\* CrCl (Cockcroft-gault formula) will be calculated using Cockcroft-Gault formula CrCL (mL\u002Fmin) = \\[(140-age) × weight (kg) × f \\]\u002F(SCR (mg\u002FdL) × 72) F = 0.85; SCR = serum creatinine. II. Urine protein \\\u003C 2 + or 24 h (h) urine protein quantification \\\u003C 1.0 g.\n\n   C) liver:\n\n   I. Serum total bilirubin (TBil)≤1.5 × ULN II. AST and ALT ≤2.5 × ULN III. Alb (Alb)≥28GL\n\n   D) coagulation function:\n\n   I. International standard ratio (INR) and activated partial thromboplastin time (APTT)≤1.5 × ULN.\n\n   E) cardiac function:\n\n   I. Left ventricular ejection fraction (LVEF)≥50% .\n9. A fertile female subject must have a urine or serum pregnancy test within 3 days before the first dose (if the urine pregnancy test result can not be confirmed as negative, a serum pregnancy test is required, whichever is the serum pregnancy result) , and the results were negative. If a fertile female subject has sex with an unsterilized male partner, the subject must use an acceptable method of contraception from the beginning of the screening process, consent must also be given to the method of contraception used prior to its continued use for 120 days after the last administration of the study drug; discontinuation of contraception after this time point should be discussed with the investigator.\n10. Subjects were willing and able to comply with schedule visits, treatment protocols, laboratory tests, and other requirements of the study.\n\nExclusion Criteria:\n\n1. Ovarian cancer of non-epithelial origin, fallopian tube cancer, primary peritoneal cancer (such as germ cell tumors) , and low-malignant potential ovarian tumors (such as borderline tumors) .\n2. Previous (within 5 years) or concurrent with other malignancies, the local tumors that have been cured (such as basal cell skin cancer, squamous cell skin cancer, superficial bladder cancer, cervical carcinoma in situ, breast carcinoma in situ, etc.) and breast cancer that has not recurred for more than 3 years after radical operation are excluded.\n3. Local recurrence is suitable for patients undergoing surgery.\n4. Previous radiation therapy of the abdomen and pelvis.\n5. Had received immunotherapy in the past, these include immune-checkpoint inhibitors (such as PD-1 CTLA-4 Bispecific monoclonal antibody, which allow previous use of PD-1 or PD-L1 mabs) , immune-checkpoint agonists (such as ICOS, CD40, CD137, GITR, OX40 antibodies, etc.) , and immune-cell therapies for any of the mechanisms of tumor immunity.\n6. Patients who were known to be allergic to any component of any investigational drug, had a history of severe hypersensitivity to other monoclonal antibody, and were known to have permanently discontinued the relevant therapeutic drug could not be enrolled.\n7. Participated in the treatment of an experimental drug or used an experimental device within 4 weeks before the first study administration.\n8. One week before the first dose (or 5 drug half-lives, whichever is longer) , a potent or intermediate CYP3A4 inhibitor, a P-gp or a BCRP inhibitor were received.\n9. Last systemic anti-tumor therapy, including chemotherapy, bevacizumab or its bioanalogues, was given within 3 weeks before the first dose, and anti-tumor hormone therapy was given within 2 weeks before the first dose Non-target lesions were treated with palliative local therapy within 2 weeks before the first dose Received Hapten therapy (such as interleukin, interferon, and thymosin, not including Il-11 for thrombocytopenia) within 2 weeks before the first dose; Within 1 week before the first administration, she had received Chinese herbal medicine or Chinese patent medicine with anti-tumor indication.\n10. Use of systemic glucocorticoid or other immunosuppressive drug within one week prior to initial administration, systemic glucocorticoid (i.e. not more than 10mg daily prednisone or equivalent dose of other glucocorticoid) that do not include nasal spray, inhalation or other route local glucocorticoid or physiological doses, allow for symptoms of dyspnea due to diseases such as chronic obstructive pulmonary disease, and temporary use of glucocorticoid for allergy prevention.\n11. The live vaccine was administered within 30 days of the first dose, or was planned for the duration of the study.\n12. Has an active autoimmune disease that requires systemic treatment in the past two years (such as use of disease-modifying drugs, corticosteroid, immunosuppressive therapy) , replacement therapy (such as thyroxine, insulin, or physiologic corticosteroid for adrenal or pituitary insufficiency) is not considered a systemic treatment.\n13. Active or previous history of a well-defined inflammatory bowel disease such as Crohn's disease, ulcerative colitis or chronic diarrhea.\n14. History of immunodeficiency, HIV antibody positive, current long-term use of systemic corticosteroid or other immunosuppressive agents.\n15. Subjects with known active tuberculosis (TB) and suspected active TB should be excluded by clinical examination.\n16. Known active syphilis infection.\n17. Known history of organ transplants and Hematopoietic stem cell transplants.\n18. Previous history of non-infectious pneumoniainterstitial lung disease requiring systemic glucocorticoid therapy or current presence of non-infectious pneumonia.\n19. Severe infection occurred within 4 weeks before the first dose, including but not limited to complications, sepsis, or severe pneumonia requiring hospitalization; Active infection (excluding antiviral therapy for hepatitis B or C) that has received systemic anti-infective therapy within 2 weeks before the first dose.\n20. Untreated subjects with active hepatitis B (HBsAg positive and HBV-DNA \\> 1000 copies\u002Fml (200 IU\u002Fml or above the lower limit of detection, whichever is higher) were required to receive anti-hbv therapy during study treatment for those with hepatitis B; and active hepatitis C subjects (HCV antibody positive and HCV-rna levels above the lower limit of detection) .\n21. Those who had a major surgical procedure or major trauma within 30 days before the first dose, or who had a major surgical plan within 30 days after the first dose (at the investigator's discretion) ; Minor local procedures (excluding central venous catheterization via peripheral venipuncture and intravenous port implantation) were performed within 3 days before the first dose.\n22. Known presence of central nervous system metastases, meningeal metastases, spinal cord metastases or compression.\n23. Subjects with clinical symptoms or repeated drainage of pleural effusion, pericardial effusion, or ascites.\n24. There are currently uncontrolled co-morbidities, these include, but are not limited to, symptomatic heart failure (grade 2 or higher according to the New York Heart Association functional class) , unstable angina, acute myocardial ischemia, poorly controlled arrhythmias, decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, severe active peptic ulcer disease, or gastritis, psychiatric\u002Fsocial conditions that may limit subjects' ability to comply with research requirements or affect their ability to provide written informed consent.\n25. Uncontrolled hypertension, systolic blood pressure \\> 140 mmhg or diastolic blood pressure \\> 90 mmhg after optimal medical treatment, history of Hypertensive crisis or hypertensive encephalopathy.\n26. Previous history of myocarditis, cardiomyopathy, and malignant arrhythmia. Unstable angina, myocardial infarction, heart failure or vascular disease (such as a ruptured aortic aneurysm) that requires hospitalization within 12 months of the first dose, or other cardiac lesions (such as poorly controlled arrhythmias, myocardial ischemia) that may affect the safety evaluation of the study drug.\n27. Esophageal Gastric varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, acute gastrointestinal bleeding, extensive bowel resection (partial or extensive colectomy with chronic diarrhea) , Crohn's disease, ulcerative colitis or chronic diarrhea.\n28. Any arterial thromboembolic event, NCI CTCAE version 5.0 Grade 3 or greater, venous thromboembolism, transient cerebral ischemia, or cerebrovascular accident occurred within 6 months before the first dose.\n29. Acute exacerbation of chronic obstructive pulmonary disease within 1 month of first dose.\n30. Patients with any sign of bleeding constitution, regardless of severity; patients with any bleeding or bleeding event ≥ CTCAE grade 3 within 4 weeks before the first dose.\n31. Current imaging or clinical manifestations of gastrointestinal obstruction, including incomplete obstruction.\n32. Severe bleeding tendency or Coagulopathy, or receiving thrombolytic therapy. Aspirin (\\> 325mg daily) or dipyrimidine, ticlopidine, clopidogrel, and Cilostazol are currently used or have been used recently (within 10 days before the first dose of study treatment) , and anticoagulants that require monitoring of INR (such as Warfarin) .\n33. Imaging showed that the tumor had surrounded or invaded important blood vessels, or that it was highly likely to invade important blood vessels and cause fatal massive bleeding during the follow-up study, compression of the superior vena cava, inferior vena cava or invasion of the heart.\n34. Toxicities from previous antitumour therapy did not resolve, defined as toxicities that did not return to grade 0 or 1 of NCI CTCAE version 5.0, or levels specified in the inclusion\u002Fexclusion criteria; Except for alopecia and sequelae of neurotoxicity related to previous platinum therapy. For subjects who develop irreversible toxicity and are not expected to worsen after administration of the study drug (EG, hearing loss) , it may be included in the study after consultation with the medical examiner.\n35. Local or systemic disease caused by a non-malignant tumor, or disease or symptoms secondary to the tumor, and can lead to higher medical risk and\u002For uncertainty in the evaluation of survival; Such as leukemoid reaction cancer (white blood cell count \\> 20 × 10 \\^ 9 L) , cachexia (known as weight loss of more than 10% 3 months before screening) , etc. .\n36. Known history of mental illness, substance abuse, alcohol or drug abuse.\n37. Women who are pregnant or nursing. The presence of any disease, treatment, or laboratory abnormality in the past or present may confuse the results of the study, affect the participant's participation in the study, or may not be in the best interest of the participant.",{"count":293,"type":20},39,[230],"* Major objectives To evaluate the efficacy of QL1706 combined with albumin-binding paclitaxel and bevacizumab in the treatment of platinum-resistant recurrent ovarian cancer.\n* Secondary Purpose To evaluate the safety of QL1706 in combination with albumin-binding paclitaxel and bevacizumab in the treatment of platinum-resistant recurrent ovarian cancer.\n\nExploratory analysis of the association between the efficacy of the combination regimen and biomarkers.",[297],"Platinum-resistant Recurrent Ovarian Cancer","2024-07-14",{"date":300,"type":33},"2024-07-19",{"date":302,"type":20},"2024-07",{"date":304,"type":20},"2026-06",{"name":39,"class":40},{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":91,"minAge":17,"maxAge":206,"enrollmentInfo":313,"targetDuration":4,"studyType":95,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":84},"100535404","phase-2-a-study-of-concurrent-chemoradiotherapy-followed-by-cadonilimabak104-for-newly-diagnosed-local-advanced-cervical-cancer-100535404","NCT06251388","A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer","A Prospective, Single Arm, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104) for Newly Diagnosed Local Advanced Cervical Cancer","Inclusion Criteria:\n\n* Voluntary agreement to provide written informed consent.\n* female, Age 18 -75 years.\n* Predicted survival ≥ 3 month.\n* Histologically and\u002For cytologically confirmed Squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma, FIGO 2018 stage III-IVA.\n* Unable to undergo curative surgery，Pior not received systemic therapy before CCRT, Including but not limited to radiotherapy, chemotherapy, immunotherapy, and biological therapy,etc.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n* Have at least one evaluable lesion (RECIST 1.1 criteria)\n* Adequate organ function, evidenced by the following laboratory results within 7 days prior to the study treatment.\n* participants are eligible to participate if they agree to the contraception use as per study protocol.\n* Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.\n\nExclusion Criteria:\n\n* Has received other antitumor therapy before CCRT.\n* Therapeutic evaluation of CCRT was disease progression.\n* Previously received immune checkpoint inhibitors (such as anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies, etc.), immune checkpoint agonists (such as ICOS, CD40, CD137, GITR, and Ox40 . etc.), immune cell therapy. etc. Any tumor immune mechanisms treatment .\n* With brain metastases.\n* Previously received allogeneic stem cell or parenchymal organ transplantation.\n* Previously or currently suffering from congenital or acquired immunodeficiency diseases.\n* known or suspected to have a history of allergies to similar drugs, or has a history of hypersensitivity to chimeric or humanized antibodies or fusion proteins, or is allergic to excipients of the study drug.\n* Diagnosed with HBsAg, HBcAb positive and HBV DNA copy positive, or HCVAb positive, or HIVAb positive.\n* Has received a live virus vaccine within 4 weeks of planned start of trial treatment.\n* Within the 6 months prior to enrollment, has serious cardiovascular events such as pulmonary embolism, acute myocardial infarction, congestive heart failure (New York Heart Association grade III or IV), and ≥ 2 grade ventricular arrhythmias.\n* Cerebrovascular accident within 6 months prior to enrollment.\n* Active infection requiring systemic treatment.\n* Uncontrolled hypertension, diabetes, Interstitial lung Disease, non infectious pneumonia , pulmonary fibrosis, acute lung disease, etc.\n* Required systemic treatment with glucocorticoid (\\>10 mg\u002Fday of prednisone or equivalent glucocorticoid) or other immunosuppressive agents within 14 days prior to enter the trial.\n* History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with a similar curative outcome as those mentioned above.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Pregnancy or lactation.\n* Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.",{"count":314,"type":20},50,[230],"This study will evaluate the efficacy and safety of concurrent chemoradiotherapy（CCRT）followed by cadonilimab（AK104) in high risk local advanced cervical cancer.\n\nParticipants received CCRT，efficacy evaluation of CCRT was no disease progression who maintained with AK104（10.0 mg\u002Fkg，Q3W）until drug exposure over 1 years or disease progression or intolerable toxicity.",[318],"Cervical Cancer","2024-02-01",{"date":321,"type":33},"2024-02-09",{"date":323,"type":20},"2024-02-20",{"date":325,"type":20},"2026-10-01",{"name":39,"class":40},{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":91,"minAge":4,"maxAge":4,"enrollmentInfo":334,"targetDuration":336,"studyType":22,"phases":4,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":84},"100530141","prognostic-value-of-mrd-detection-in-ca125-non-sensitive-ovarian-cancer-patients-100530141","NCT06182917","Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients","A Study for Assessing the Value of Minimal Residual Disease Detection in Disease Monitoring of CA125 Non-sensitive Ovarian Cancer Patients","Inclusion Criteria:\n\n* Age 18-75;\n* Pathologically confirmed ovarian cancer;\n* CA125 ≤200U\u002Fml at first diagnosis or recurrence;\n* Physical condition score PS ≤ 2 points;\n* Enough tumor samples for WES detection;\n* Patients and their families can understand and are willing to participate in this study and provide written informed consent.\n\nExclusion Criteria:\n\n* Patients unable to provide sufficient tissue \u002F blood samples for research detection;\n* Pregnant or lactating women;\n* Other diseases considered by the research doctor to affect the prognosis and survival;",{"count":335,"type":20},35,"2 Years","Ovarian cancer ranks third in the incidence of gynecologic malignancies, while mortality ranks first. The tumor marker CA125 is the most concerned tumor marker in the clinical monitoring prognosis of ovarian cancer, and an elevated CA125 indicates a later stage and a worse prognosis. However about 20% of patients with ovarian cancer have low CA125 expression. Therefore, CA125 is not sensitive to some ovarian cancers with a high risk of recurrence. How to improve the diagnostic performance of these CA125-insensitive patients is a difficult problem in current research. Minimal residual disease (MRD) refers to the residual tumor components in the body of tumor patients after achieving complete remission through treatment. MRD detection is mainly achieved by liquid biopsy, and residual tumor components can be detected by circulating tumor DNA (ctDNA). This study aims to explore the value of MRD (ctDNA) in the risk assessment of CA125 non sensitive ovarian cancer populations by combining ctDNA with traditional imaging and serological tumor markers.",[339],"Ovarian Cancer","2023-12-26",{"date":342,"type":33},"2023-12-27",{"date":344,"type":33},"2023-10-01",{"date":346,"type":20},"2026-06-30",{"name":39,"class":40},{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":11,"sex":91,"minAge":4,"maxAge":355,"enrollmentInfo":356,"targetDuration":4,"studyType":95,"phases":358,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":84},"100321314","phase-2-value-of-lng-ius-as-fertility-preserving-treatment-of-eah-and-ec-100321314","NCT03463252","Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC","Value of Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Fertility-preserving Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma","For Patients With Endometrial Cancer：\n\nInclusion Criteria:\n\n* ≤40 years of age:\n* Having a strong desire for fertility preservation;\n* Histological diagnosis is confirmed as well-differentiated (grade 1) endometrioid adenocarcinoma by the designated gynecological pathologists, and the progesterone receptors (PgRs) is positive in immunohistochemistry;\n* Disease limited to the endometrium (stage 1A) on MRI;\n* Serum CA125\u002F199 level is within normal limit (Laparoscopic exploration to rule out ovarian tumor or another metastasis if necessary);\n* Patients should have undergone counseling to learn fertility-preserving treatment is not standard of care for the treatment of EC, volunteered to participate in this study, signed the informed consent form, and agreed to participated in clinical follow-up.\n\nExclusion Criteria:\n\n* Patients have allergies or contraindications (except for thromboembolic disease, liver dysfunction, hypertension, and diabetes) for the involved drugs;\n* Patients have lynch syndrome (LS);\n* Patients have contraindications for pregnancy;\n* Patients have serious underlying disease, malignancies at other site(s), acute liver or kidney disease, acute liver or kidney diseases, acute or subacute genital tract infections and congenital or acquired abnormal uterine development (that may make intrauterine device placement impossible);\n* Patients refuse to participate in clinical follow-up or sign the informed consent form.\n\nFor Patients With Endometrial atypical hyperplasia：\n\nInclusion Criteria:\n\n* ≤ 40 years of age\n* Having a strong desire for fertility preservation\n* Histological diagnosis is confirmed as atypical endometrial hyperplasia (EAH) by the designated gynecological pathologists\n* Having volunteered to participate in this study, signed the informed consent form, and agreed to participate in clinical follow-up\n\nExclusion Criteria:\n\n* Patients have allergies or contraindications (except for thromboembolic disease, liver dysfunction, hypertension, and diabetes) for the involved drugs\n* Patients have contraindications for pregnancy\n* Patients have serious underlying disease, malignancies at other site(s), acute liver or kidney disease, acute or subacute genital tract infections, and congenital or acquired abnormal uterine development (that may make intrauterine device placement impossible)\n* Patients refuse to participate in clinical follow-up or sign the informed consent form.","40 Years",{"count":357,"type":20},224,[230,359],"PHASE3","Primary end points:\n\nThis clinical trial is aimed to analyze the effectiveness of Levonorgestrel-Releasing Intrauterine System (LNG-IUS, Mirena®) in the fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma, including pathology response and pregnancy outcome.\n\nSecond end points:\n\nTo analyze the appearances of side-effects.",[362,363],"Endometrial Cancer","Atypical Endometrial Hyperplasia","2021-09-03",{"date":366,"type":33},"2021-09-13",{"date":368,"type":33},"2018-04-01",{"date":370,"type":20},"2030-12-30",{"name":39,"class":40},""]